CNSP.US CNS Pharmaceuticals Inc

Healthcare Pharmaceuticals USA Stocks
2.89 USD
Close of Nov 14, 2026
1.90 10.54
Market cap
USD 4.22M
P/E
-
P/B
0.29x
ROE
-82.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is CNSP.US undervalued?

Graham number

The Graham number of CNS Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CNS Pharmaceuticals Inc fundamental analysis

No fundamental analysis for CNS Pharmaceuticals Inc yet.

CNS Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CNS Pharmaceuticals Inc

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemoth…

Full company profile